Germany has significantly improved the attractiveness of early clinical development through the Medical Research Act (Medizinforschungsgesetz, MFG) to expedite the approval of mononational clinical trials. Sponsors conducting innovative studies in Germany can benefit from accelerated regulatory processes, streamlined ethics review, standardized contracting, and access to leading academic centers.
Executive Summary for Sponsors
Why Consider Germany?
- Accelerated start-up timelines for Germany-only studies
- More efficient regulatory and ethics review processes
- Standardized clinical trial agreements to reduce contract negotiations
- Access to world-class investigators and research hospitals
- Particularly attractive for FIH, Phase I/II, device, gene therapy, and cell therapy programs
- Transparent implementation of a “guard rail concept” for study protocols in early-phase clinical trials
Recommended Strategy
Many sponsors now consider a Germany-first approach: initiate an early-phase study in Germany to generate clinical data rapidly, then expand into broader European or global development.
Key Regulatory Resources
Federal Ministry of Health (Medical Research Act)
European Clinical Trials Information System (CTIS)
European Medicines Agency (EMA)
How SCIRENT Can Help
SCIRENT is a specialized full-service CRO with extensive experience in cardiovascular, medical device, gene therapy, and cell therapy trials. We help sponsors leverage Germany’s new regulatory framework to accelerate study start-up while maintaining the highest scientific and operational standards.
Our team supports every stage of your project, including regulatory strategy, protocol optimization, authority and ethics submissions, site identification and feasibility, contract negotiations, project management, clinical operations, medical monitoring, data management, biostatistics, and vendor oversight.
Through our established network of leading German investigators and research sites, we help sponsors reduce start-up timelines, mitigate operational risks, and reach First Patient In as quickly as possible.
Get Started
If you are planning an early-phase clinical trial, contact SCIRENT to discuss whether a Germany-first strategy could accelerate your development program. Our team would be pleased to evaluate your project and provide an initial regulatory and operational assessment.